Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data demonstrating that KIO-300, a novel ion channel modulator, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA.
KIO-300 is the active pharmaceutical ingredient of KIO-301, which is currently in a Phase 2 clinical program for vision restoration in patients with gene mutation-agnostic retinitis pigmentosa. This new data suggests potential expansion of the platform into neurology, specifically epilepsy. The preclinical study showed a significant reduction in epileptiform activity, indicating that KIO-300 could modulate ion channels involved in seizure generation.
For leaders in business and technology, this announcement signals Kiora's ability to repurpose its ion channel modulator technology across therapeutic areas. The company, a clinical-stage biotechnology firm, is developing advanced therapies for retinal disease but may now have a candidate for neurological disorders. The implications are substantial: if KIO-300 progresses to clinical trials and demonstrates efficacy in epilepsy, it could address a significant unmet need in temporal lobe epilepsy, a condition often resistant to existing treatments.
Kiora Pharmaceuticals targets critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed initially for retinitis pigmentosa, with potential to expand into choroideremia and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is another candidate being developed for macular edema due to retinal inflammation.
The company's forward-looking statements highlight risks and uncertainties, including the ability to conduct clinical trials on a timely basis and the potential for KIO-301 and KIO-104 to address multiple indications. However, the preclinical epilepsy data opens a new avenue for pipeline expansion. For investors and industry observers, this diversification could mitigate risk and broaden the company's market opportunity.
The Epilepsy Foundation Pipeline Conference serves as a key platform for showcasing emerging therapies. Kiora's presentation there underscores its commitment to exploring new indications. As the company continues to develop its ion channel modulator platform, the potential impact on patients with epilepsy and other neurological conditions could be transformative. Business leaders should monitor Kiora's progress as it navigates the path from preclinical to clinical development.
For more information, visit Kiora's website at www.kiorapharma.com.
